Bumetanide（CAS:28395-03-1)

Bumetanide, CAS registered number 28395-03-1, is a high-efficiency and classic loop diuretic pharmaceutical API in the global pharmaceutical industry. As an upgraded product of furosemide, Bumetanide has become a core raw material for clinical treatment and pharmaceutical manufacturing due to its superior pharmacological performance, stable chemical properties and high safety factor. With stable molecular structure, low impurity content and high purity, this chemical compound fully meets international pharmacopoeia standards and can be processed into oral tablets, injections and other pharmaceutical preparations, occupying an important position in the field of diuretic drugs.

In terms of pharmacological mechanism, Bumetanide has an accurate action target, mainly acting on the thick ascending limb of the renal medullary loop in human kidneys. It can effectively block the reabsorption of sodium, potassium and chloride ions in renal tubules, significantly increase the excretion of water and electrolytes, and rapidly eliminate water and sodium retention in the body. Its diuretic potency is extremely prominent, about 40 to 50 times higher than furosemide. It can achieve an ideal therapeutic effect at a very low dosage, which greatly reduces the risk of adverse reactions caused by high-dose medication. In terms of efficacy speed, Bumetanide takes effect rapidly. Oral administration works within half an hour, and intravenous injection takes effect in a few minutes. Its stable and lasting drug effect avoids sudden fluctuations in treatment effect, making it suitable for both emergency treatment of acute diseases and long-term treatment of chronic diseases.

Clinically, Bumetanide has a wide range of applicable diseases and is the preferred raw material for various edematous diseases. It is widely used in the treatment of congestive heart failure, which can quickly reduce cardiac load, improve cardiopulmonary circulation, and relieve systemic edema and pulmonary edema. For intractable edema caused by acute and chronic nephritis, renal failure and nephrotic syndrome, Bumetanide shows stable and reliable therapeutic effects. Different from other diuretics, it has little irritation to the kidney and will not aggravate renal damage, so it is especially suitable for patients with insufficient renal function. In addition, it can also assist in the treatment of hepatic edema and ascites caused by liver cirrhosis, and can be used as an auxiliary drug for refractory hypertension to stabilize blood pressure by excreting excess water and sodium in the body.

In terms of safety and industrial application, Bumetanide has milder side effects than similar diuretics. Under conventional therapeutic doses, the incidence of adverse reactions is extremely low. A small number of mild symptoms such as electrolyte disorder and gastrointestinal discomfort can be relieved by adjusting the dosage without serious organ toxicity and drug accumulation toxicity. It supports diverse administration methods and individualized treatment. At present, the mature synthetic process ensures the high purity and stable quality of Bumetanide API. The product complies with international pharmaceutical standards, with sufficient supply and scalable production capacity. It is widely supplied to pharmaceutical factories, scientific research institutions and drug research and development enterprises all over the world. With high cost performance and reliable efficacy, Bumetanide has become one of the most mainstream and promising diuretic pharmaceutical raw materials in the global pharmaceutical market.